INSTITUT PASTEUR
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1887-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.pasteur.fr/en
Clinical Trials
95
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (62 trials with phase data)• Click on a phase to view related trials
Effectiveness of Speech Therapy for Lip-reading in Patients With Hearing Aids: SCED Study
- Conditions
- Hearing Loss, Bilateral or Unilateral
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Institut Pasteur
- Target Recruit Count
- 8
- Registration Number
- NCT07028658
Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI
- Conditions
- Leptospirosis
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Institut Pasteur
- Target Recruit Count
- 450
- Registration Number
- NCT06945822
Exploring the Links Between Hearing, Cognition and Brain Activity in People With Tinnitus
- Conditions
- Tinnitus
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Institut Pasteur
- Target Recruit Count
- 114
- Registration Number
- NCT06940726
Study of Auditory Perception After Progressive Exposure to Aversive Sounds in People With Misophonia
- Conditions
- Misophonia
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Institut Pasteur
- Target Recruit Count
- 110
- Registration Number
- NCT06921187
- Locations
- 🇫🇷
Centre de Recherche en Psychologie et Neuroscience (CRPN), Marseille, France
🇫🇷CEntre de Recherche et d'Innovation en Audiologie Humaine, Paris, France
Host Immunity, Plasmodium and Pathogens Co-Infections
- Conditions
- MalariaBacterial Co-infection
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Institut Pasteur
- Target Recruit Count
- 2000
- Registration Number
- NCT06769815
- Prev
- 1
- 2
- 3
- 4
- 5
- 18
- Next
News
SpikImm Secures Worldwide License for Anti-BK Virus Monoclonal Antibodies to Protect Transplant Patients
SpikImm signed an exclusive worldwide licensing agreement with SATT Conectus for potent monoclonal antibodies targeting BK virus, addressing a critical unmet need in transplant medicine.
Oncovita Receives FDA Orphan Drug Designation for Oncolytic Measles Virus Therapy in Pleural Mesothelioma
Oncovita's MVdeltaC, a genetically modified measles virus immunotherapy, has received FDA Orphan Drug Designation for treating pleural mesothelioma, a rare and aggressive cancer affecting approximately 3,000 Americans annually.
Sensorion Completes Patient Enrollment in Phase 2a Trial of SENS-401 for Cisplatin-Induced Hearing Loss Prevention
Sensorion has enrolled the final patient in its NOTOXIS Phase 2a trial evaluating SENS-401 for preventing hearing loss caused by cisplatin chemotherapy, with 47 patients randomized across treatment and control groups.
Enodia Therapeutics Launches with Novel Protein Degradation Platform Targeting Cancer and Inflammatory Diseases
Argobio and Institut Pasteur have launched Enodia Therapeutics, a French biotech developing first-in-class treatments targeting the Sec61/translocon complex for protein degradation.
Early HIV Treatment Shows Promise for Long-Term Viral Control
Initiating antiretroviral therapy (ART) within weeks of HIV infection may allow for long-term viral control even after treatment is stopped, according to a new study.